Redwood Pharma AB (OTCMKTS:REDW) Stock Surges After Positive Results From A Clinical Study With Rp501 Against Dry Eye

A company that may well come into focus today is Redwood Pharma AB (OTCMKTS:REDW) after the company announced positive results from the clinical study with RP501 for dry eye. RP501 is a medical technology self-care product that had been developed for the purpose of treating dry eye.

Trading Data

On Wednesday, REDW stock increased 4.28% to $0.4630 with more than 2.16 million shares traded, compared to volume of 1.13 million shares. The stock moved within a range of $0.4390 – 0.6100 after opening trading at $0.5000.

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

The company announced yesterday that the results from the clinical study revealed that the product was not only safe but well tolerated. Additionally it also produced statistically significant result with regards to some of the more important aspects of dry eye like stinging, burning sensation and itching. In the study, the company tested the efficacy, tolerability and safety of the product by testing it on people who suffered from dry eye.

64 subjects in total had been the subject of the study and they had been divided into two groups. The two groups of patients had been treated for a period of 84 and 33 days respectively. The product managed to produce statistically significant results for most of the 10 subjective parameters of the study. It was also noted that the ease of use was another factor that had also been appreciated by the test subjects.